These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 21922523

  • 1. Iron overload and stem cell transplant-and the beat goes on.
    Tefferi A.
    Am J Hematol; 2011 Oct; 86(10):825-6. PubMed ID: 21922523
    [No Abstract] [Full Text] [Related]

  • 2. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo.
    Alessandrino EP, Angelucci E, Cazzola M, Porta MG, Di Bartolomeo P, Gozzini A, Malcovati L, Pioltelli P, Sica S, Bosi A.
    Am J Hematol; 2011 Oct; 86(10):897-902. PubMed ID: 21809371
    [No Abstract] [Full Text] [Related]

  • 3. Iron chelation therapy in myelodysplastic syndromes: we need more evidence, not more guidelines.
    Butler A, Patton WN.
    Intern Med J; 2012 May; 42(5):481-4. PubMed ID: 22616959
    [No Abstract] [Full Text] [Related]

  • 4. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
    Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, Sill H, Bettelheim P, Pfeilstöcker M.
    Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation therapy in low risk myelodysplastic syndrome.
    Killick SB.
    Br J Haematol; 2017 May; 177(3):375-387. PubMed ID: 28300275
    [Abstract] [Full Text] [Related]

  • 6. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL.
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP, Yang YS, Yao CY, Peng CT.
    Hemoglobin; 2009 Jan; 33(5):339-45. PubMed ID: 19814680
    [Abstract] [Full Text] [Related]

  • 8. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
    Steensma DP.
    Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
    [Abstract] [Full Text] [Related]

  • 9. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
    Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB.
    Intern Med J; 2012 Apr; 42(4):450-5. PubMed ID: 22498118
    [Abstract] [Full Text] [Related]

  • 10. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
    Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R.
    J Natl Compr Canc Netw; 2009 Dec 29; 7 Suppl 9():S1-16. PubMed ID: 20064286
    [Abstract] [Full Text] [Related]

  • 11. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.
    Abraham I, Yami MA, Yun S, Kim HJ, Vincelette ND, McBride A, MacDonald K.
    Leuk Res; 2017 Jun 29; 57():104-108. PubMed ID: 28343141
    [No Abstract] [Full Text] [Related]

  • 12. Iron overload and chelation.
    Hershko C, Link G, Konijn AM, Ioav Cabantchik Z.
    Hematology; 2005 Jun 29; 10 Suppl 1():171-3. PubMed ID: 16188664
    [Abstract] [Full Text] [Related]

  • 13. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar 29; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 14. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
    Ko BS, Chang CS, Chang MC, Chen TY, Chiou TJ, Chiu CF, Huang WL, Kao WY, Lan YJ, Lin SF, Tan TD, Tang JL, Tzeng CH, Wang PN, Yet SP, Tien HF.
    Int J Hematol; 2014 Jul 29; 100(1):7-15. PubMed ID: 24924953
    [Abstract] [Full Text] [Related]

  • 15. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
    Mitchell M, Gore SD, Zeidan AM.
    Expert Rev Hematol; 2013 Aug 29; 6(4):397-410. PubMed ID: 23991926
    [Abstract] [Full Text] [Related]

  • 16. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG, Nagler A.
    Expert Rev Anticancer Ther; 2014 Jul 29; 14(7):817-29. PubMed ID: 24641787
    [Abstract] [Full Text] [Related]

  • 17. [Post-transfusional iron overload, iron loading anemia].
    Rose C.
    Rev Med Interne; 2012 Jun 29; 33 Suppl 1():S15-8. PubMed ID: 22475955
    [No Abstract] [Full Text] [Related]

  • 18. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan 29; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 19. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F, Phatak P.
    Expert Rev Hematol; 2017 Jan 29; 10(1):53-64. PubMed ID: 27923273
    [Abstract] [Full Text] [Related]

  • 20. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug 29; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.